Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma
Clinical trial NCT05590221 · UNKNOWN
Trial details
- NCT number
- NCT05590221
- Sponsor
- Peking University Cancer Hospital & Institute
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-01-03
- Primary completion
- 2024-02-10
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.